Research Funding

Research reported in this publication was supported by the following sources and grants from the National Institutes of Health (NIH):

Scientists Identify Genetic Variation Linked to Severity of ALS: Hope for Tomorrow, a gift in the memory of Murray Sherman, the Wake Forest Baptist Health Brian White Fund and the Tab A. Williams Funds at Wake Forest School of Medicine.

Player Athleticism Increases Head Impact Exposure in Youth Football: National Institute of Neurological Disorders and Stroke awards R01 NS094410 and R01 NS082453, National Center for Advancing Translational Sciences grant KL2 TR001421 and the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center.

Intensive Blood Pressure Control May Slow Age-Related Brain Damage: NIH Systolic Blood Pressure Intervention Trial, which was jointly funded by the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke (HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C and interagency agreement A-HL-13-002-001), and the following NIH grants: OD023495, TR000439, RR025755, RR024134, TR000003, RR025771, TR000093, RR025752, TR000073, TR001064, TR000050, TR000005, TR000017, TR000105, TR000445, TR000075, TR000002, TR000064, TR000433, GM103337. Additional funding was provided by the Department of Veterans Affairs. Azilsartan and chlorthalidone (combined with azilsartan) were provided by Takeda Pharmaceuticals International Inc.